Title: Drug-eluting stent trials: too much non-inferiority, too little progress?
Abstract: Drug-eluting stents have revolutionised the treatment of coronary artery disease, delivering reduced rates of treatment failure across the range of disease presentations and allowing for the expansion of catheter-based revascularisation to patients with complex disease patterns. 1 Byrne RA Sarafoff N Kastrati A Schomig A Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. 2009; 32: 749-770 Crossref PubMed Scopus (66) Google Scholar Nevertheless, the efficacy of these devices in preventing restenosis occurs at the expense of a delay in healing of the stented artery, which underlies, among other things, a small but relevant increase in late adverse events such as stent thromboses, at least with early-generation devices. Subsequent development has produced improved devices with lower drug loads, thinner stent struts, and more biocompatible polymer coatings, and these refinements have further improved patient outcomes. 2 Stefanini GG Holmes Jr, DR Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368: 254-265 Crossref PubMed Scopus (555) Google Scholar Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialBoth stents were similarly efficacious and safe, and provided excellent clinical outcomes, especially in view of the large number of patients who presented with acute myocardial infarctions. Full-Text PDF
Publication Year: 2013
Publication Date: 2013-10-31
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 14
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot